Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice...will be very pleased with 1/2 that target...🥳
Bought a starter today.
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
12:54 PM ET 8/15/24 | Dow Jones
TPST...$1.50...Off the .90 range dip...🥳...was $6 recently...setting up for a Breakout...imo...we shall see...
TPST...1.4995...HOD...Beauty move off the .90 range dip...🥳Was $6 a couple of months ago...🥳
TPST...$1.24...🥳...BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma (HCC).
"We are thrilled with the positive outcome of our end-of-Phase 2 meeting with the FDA,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest. “Tempest and the FDA are in broad agreement on all major aspects of the proposed pivotal Phase 3 clinical trial for amezalpat in patients with hepatocellular carcinoma in the first line setting. This planned Phase 3 study closely mirrors the randomized Phase 2 study and the strongly favorable hazard ratio for overall survival observed at top-line analysis of the Phase 2, confirmed at the latest survival follow-up, give us confidence in the potential success of the Phase 3.”
Key outcomes of the FDA meeting include:
Agreement on Phase 3 study design, including the standard-of-care control arm and the primary and secondary study endpoints
Agreement on appropriateness of the current amezalpat dose and schedule for the Phase 3 study
Agreement on the Phase 3 statistical plan including a pre-specified early efficacy analysis that the company currently estimates could shorten the time to primary analysis by up to 8 months
TPST...$1.05...Setting up Bullish Harami...Reversal Pattern...🥳
TPST...$1.16...Taking a hit on earnings...adding more down here...🥳
TPST...$1.80...setting up Reversal Candle here...adding...🥳
Yup...nice buy for the CEO...🥳
Lol offering upsized right after the news..
in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m.
yup and time to go up even more let's pass 7 and up trmw
UPstink today
Any other bio cheapies besides hook
Was that you 3.12 big
FROM 2.92 MY CALL.NOW 3.38:))))
AS OF NOW PER SCHWAB IT IS VERY HARD TO FIND SHARES TO SHORT.WELL THAT IS GOING TO BE A B$TCH FOR SHORTS.
ORCA IS LOOKING TO GET BACK IN AGAIN.THE PPS IS COMING DOWN TO MY ENTERING PRICES:)))
“Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”
Grabbed $3.50’s..should find out who they partnered with..soon enough
Up 12% 2nd million..let’s see 3rd
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
593
|
Created
|
04/04/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |